GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019
November 05, 2019 16:00 ET
|
GW Pharmaceuticals plc
- Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million - - Conference call today at 4:30 p.m. ET - CARLSBAD, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- GW...
GW Pharmaceuticals to Present at Upcoming Investor Conferences
October 31, 2019 07:00 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019
October 09, 2019 07:00 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019
September 24, 2019 12:38 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
September 23, 2019 07:00 ET
|
GW Pharmaceuticals plc
Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
September 23, 2019 07:00 ET
|
GW Pharmaceuticals plc
Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived...
GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019
September 04, 2019 08:22 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019
August 06, 2019 16:01 ET
|
GW Pharmaceuticals plc
- Epidiolex U.S. Q2 net sales of $68.4 million - - Positive CHMP opinion clears way for an expected European approval in October - - Conference call today at 4:30 p.m. EST - CARLSBAD, Calif., Aug. ...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
July 26, 2019 06:46 ET
|
GW Pharmaceuticals plc
If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy GW’s cannabidiol oral solution...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
July 26, 2019 06:37 ET
|
GW Pharmaceuticals plc
If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy GW’s cannabidiol oral solution...